# relapsed/refractory diffuse large B-cell lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-refractory-diffuse-large-b-cell-lymphoma

> 4 upcoming FDA catalysts in relapsed/refractory diffuse large B-cell lymphoma: selinexor (combination therapy, KPTIQ) on December 2026 (primary completion); selinexor (combination therapy, KPTIQ) on Dec 2026 to Mar 2027 (topline data readout); HMPL-760 (HCM) on Apr to Jul 2028 (topline data readout); HMPL-760 (HCM) on April 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 23, 2026 | [HMPL-760 trial start](https://sec-api.dev/pdufa/hmpl-760) | HCM | relapsed/refractory diffuse large B-cell lymphoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, March 23, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000021/hcm-20260323xex99d1.htm)) |
| May 23, 2026 | [Hmpl-760 planned dose 1 primary completion](https://sec-api.dev/pdufa/hmpl-760-planned) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT06601504 (Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-23 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06601504)) |
| December 2026 | [Selinexor (combination therapy) primary completion](https://sec-api.dev/pdufa/selinexor-combination-therapy) | KPTIQ | Relapsed/Refractory Diffuse Large B-cell Lymphoma | scheduled | "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04442022)) |
| Dec 2026 to Mar 2027 | [Selinexor (combination therapy) topline data readout](https://sec-api.dev/pdufa/selinexor-combination-therapy) | KPTIQ | Relapsed/Refractory Diffuse Large B-cell Lymphoma | scheduled | "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04442022)) |
| Apr to Jul 2028 | [HMPL-760 topline data readout](https://sec-api.dev/pdufa/hmpl-760) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | scheduled | "NCT07409428 (A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07409428)) |
| April 2028 | [HMPL-760 primary completion](https://sec-api.dev/pdufa/hmpl-760) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | scheduled | "NCT07409428 (A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07409428)) |

## Drugs

- [HMPL-760](https://sec-api.dev/pdufa/hmpl-760) (HCM)
- [Hmpl-760 planned dose 1](https://sec-api.dev/pdufa/hmpl-760-planned) (HCM)
- [Selinexor (combination therapy)](https://sec-api.dev/pdufa/selinexor-combination-therapy) (KPTI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-refractory-diffuse-large-b-cell-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "relapsed/refractory diffuse large B-cell lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-refractory-diffuse-large-b-cell-lymphoma

```bibtex
@misc{secapidev_indications_relapsed_refractory_diffuse_large_b_cell_lymphoma_20261116,
  title        = {relapsed/refractory diffuse large B-cell lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-refractory-diffuse-large-b-cell-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_refractory_diffuse_large_b_cell_lymphoma_20261116","title":"relapsed/refractory diffuse large B-cell lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-refractory-diffuse-large-b-cell-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
